We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
-19.37%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$563M
AUM Growth
-$292M
Cap. Flow
-$116M
Cap. Flow %
-20.64%
Top 10 Hldgs %
61.97%
Holding
58
New
11
Increased
10
Reduced
6
Closed
19

Top Buys

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$39.1M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$30.4M
3
XENE icon
Xenon Pharmaceuticals
XENE
+$24.7M
4
KROS icon
Keros Therapeutics
KROS
+$23.2M
5
ETNB
89bio
ETNB
+$21.9M

Top Sells

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$42.3M
2
VERA icon
Vera Therapeutics
VERA
+$37M
3
MRUS
Merus
MRUS
+$31.5M
4
INSM icon
Insmed
INSM
+$31.1M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$27.3M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELVN icon
26
Enliven Therapeutics
ELVN
$3.77B
$4.72M 0.84%
240,000
+100,000
+71% +$2.15M
IMVT icon
27
Immunovant
IMVT
$8.23B
$4.7M 0.84%
275,000
-25,000
-8% -$523K
JBIO
28
Jade Biosciences
JBIO
$1.21B
$3.51M 0.62%
40,000
– –
ACRS icon
29
Aclaris Therapeutics
ACRS
$750M
$3.4M 0.6%
2,222,222
– –
UNCY icon
30
Unicycive Therapeutics
UNCY
$141M
$2.92M 0.52%
507,893
– –
TRVI icon
31
Trevi Therapeutics
TRVI
$2.57B
$2.67M 0.47%
424,715
-825,285
-66% -$3.94M
ATXS
32
DELISTED
Astria Therapeutics
ATXS
$2.67M 0.47%
500,000
– –
RAPP
33
Rapport Therapeutics
RAPP
$2.01B
$2.1M 0.37%
208,910
– –
CBIO
34
Crescent Biopharma
CBIO
$626M
$1.13M 0.2%
54,000
– –
SEPN
35
Septerna Inc
SEPN
$1.51B
$777K 0.14%
134,202
– –
ALLK
36
DELISTED
Allakos
ALLK
$660K 0.12%
2,900,000
– –
ARTV
37
Artiva Biotherapeutics
ARTV
$501M
$435K 0.08%
145,089
– –
SLDB icon
38
Solid Biosciences
SLDB
$777M
$370K 0.07%
+100,000
New +$428K
NUVB.WS
39
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$15.9K ﹤0.01%
66,666
– –
ALKS icon
40
Alkermes
ALKS
$8.79B
– –
-500,000
Closed -$14.4M
APGE icon
41
Apogee Therapeutics
APGE
$10.2B
– –
-300,000
Closed -$13.6M
APLS
42
DELISTED
Apellis Pharmaceuticals
APLS
– –
-500,000
Closed -$16M
ARVN icon
43
Arvinas
ARVN
$530M
– –
-700,000
Closed -$13.4M
BPMC
44
DELISTED
Blueprint Medicines
BPMC
– –
-200,000
Closed -$17.4M
CYTK icon
45
Cytokinetics
CYTK
$10.9B
– –
-900,000
Closed -$42.3M
DRUG
46
Bright Minds Biosciences
DRUG
$706M
– –
-245,000
Closed -$8.82M
EWTX icon
47
Edgewise Therapeutics
EWTX
$4.48B
– –
-400,000
Closed -$10.7M
INSM icon
48
Insmed
INSM
$22.7B
– –
-450,000
Closed -$31.1M
JAZZ icon
49
Jazz Pharmaceuticals
JAZZ
$16B
– –
-175,000
Closed -$21.6M
MRUS
50
DELISTED
Merus
MRUS
– –
-750,000
Closed -$31.5M
1
2
3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q1 2025 Portfolio in Review

As of Q1 2025, Logos Global Management held 58 positions worth $563M, down 34% from $855M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Logos Global Management withdrew a net $116M in Q1 2025, closing 19 positions and reducing 6 holdings. Its most notable exit was Cytokinetics, an estimated $42.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, Logos Global Management opened a new position in Nuvalent worth $35.5M.

  • Logos Global Management's largest Q1 2025 buy was Nuvalent: 500,000 shares worth $35.5M.
  • Logos Global Management added most to Akero Therapeutics in Q1 2025, an estimated $17M increase.
  • Logos Global Management's biggest Q1 2025 reduction was BioNTech, cutting an estimated $11.2M.
  • Logos Global Management fully exited Cytokinetics in Q1 2025, selling an estimated $42.3M.
  • Logos Global Management's ten largest holdings make up 62% of its $563M portfolio in Q1 2025.
  • Logos Global Management opened 11 new positions and closed 19 in Q1 2025.
  • Logos Global Management's portfolio value fell 34% quarter-over-quarter to $563M.

Based on Logos Global Management's 13F filing for Q1 2025, filed 15 May 2025.